Literature DB >> 2481854

Effect of uridine diphosphoglucose on levels of 5-phosphoribosyl pyrophosphate and uridine triphosphate in murine tissues.

J R Colofiore1, R C Sawyer, M E Balis, D S Martin.   

Abstract

The purpose of the present investigation was to determine whether a single bolus intravenous injection (2000 mg/kg) of uridine diphosphoglucose (UDPG) could affect levels of PRPP in a transplanted mammary adenocarcinoma and in liver of CD8FI mice. Six hours following a single intravenous injection of UDPG, 2000 mg/kg, tumor PRPP was lowered to 80 pmol/mg protein, a 53% decrease compared to saline control tumors. Liver was more sensitive than tumor to the 5-phosphoribosyl pyrophosphate (PRPP)-depleting effects of a single bolus intravenous injection of UDPG, since significantly lower levels of PRPP were found in liver, but not in tumor, at doses of 500-1000 mg/kg of UDPG. Maximal depression (30% of saline control) or PRPP occurred in liver 6 hr after intravenous UDPG at 1000-2000 mg/kg. Enhanced levels of UDPG in plasma (half-life less than 10 min) and tumor was detected at 30 min after intravenous UDPG at 2000 mg/kg. There was no detectable increase in endogenous levels of UDPG in liver at this time, probably as a result of rapid metabolism of UDPG by liver. At this same time, a twofold increase in uridine triphosphate (UTP) was measured in liver after intravenously administered UDPG. In contrast, the level of UTP was not increased significantly above control values in tumor. These data suggest the potential use of UDPG to elevate UTP pools in normal tissues in the delayed rescue of cancer chemotherapeutic drugs such as 5-fluorouracil which function as a uridine analogue in these tissues.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2481854     DOI: 10.1023/a:1015908505351

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  10 in total

1.  Comparison of the properties of phosphoribosylpyrophosphate synthetase in normal and leukemic human white blood cells.

Authors:  M K Danks; E M Scholar
Journal:  Biochem Pharmacol       Date:  1979-09-15       Impact factor: 5.858

2.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

Review 3.  Spontaneous murine mammary adenocarcinoma: model system for evaluation of combined methods of therapy.

Authors:  R L Stolfi; D S Martin; R A Fugmann
Journal:  Cancer Chemother Rep       Date:  1971-06

4.  Enhancement of 5-fluorouracil incorporation into human lymphoblast ribonucleic acid.

Authors:  D W Kufe; E M Egan
Journal:  Biochem Pharmacol       Date:  1981-01-15       Impact factor: 5.858

5.  Modulation of 5-FU metabolism in human MCF-7 breast carcinoma cells.

Authors:  P P Major; E M Egan; L Sargent; D W Kufe
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

6.  The selectivity of action of methotrexate in combination with 5-fluorouracil in xenografts of human colon adenocarcinomas.

Authors:  J A Houghton; A J Tice; P J Houghton
Journal:  Mol Pharmacol       Date:  1982-11       Impact factor: 4.436

7.  Improved therapeutic index with sequential N-phosphonacetyl-L-aspartate plus high-dose methotrexate plus high-dose 5-fluorouracil and appropriate rescue.

Authors:  D S Martin; R L Stolfi; R C Sawyer; S Spiegelman; C W Young
Journal:  Cancer Res       Date:  1983-10       Impact factor: 12.701

8.  High-dose 5-fluorouracil with delayed uridine "rescue" in mice.

Authors:  D S Martin; R L Stolfi; R C Sawyer; S Spiegelman; C W Young
Journal:  Cancer Res       Date:  1982-10       Impact factor: 12.701

9.  Enhanced 5-fluorouracil nucleotide formation after methotrexate administration: explanation for drug synergism.

Authors:  E Cadman; R Heimer; L Davis
Journal:  Science       Date:  1979-09-14       Impact factor: 47.728

10.  Effects of uridine diphosphoglucose (UDPG) infusion on 5-phosphoribosyl pyrophosphate (PRPP) levels of mouse tissues.

Authors:  L C Yip; Y L Xu; M E Balis
Journal:  Biochem Pharmacol       Date:  1987-03-01       Impact factor: 5.858

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.